POS0130 from #EULAR2022 found only a 50% concordance between PsO patients with self-reported MSK pain and US findings of PsA. Remember, not all pain in PsO is PsA. @RheumNow https://t.co/CiMUa9HNgk

🦶🏼What drives positivity of famous Squeeze test in MTPs in RA? MRI correlation study finds: -in early RA, association w/ *Synovitis OR 3.2 and Inter-metatarsal bursitis OR 4.8 -in pts in remission *Sub clinical synovitis only OR 2.5 @RheumNow #EULAR2022 OP0290 https://t.co/2CNUsaesaG

Prof van Lear defines Difficult to Treat (D2T) RA: Failed >2 b/tsDMARD w/diff't MOA after failing csDMARD AND signs of active/progressing disease: DAS28 ESR >3.2 or CDAI>10, high ESR/CRP, imaging, Sx's causing low QoL, pred>7.5 mg/d, rapid xray progression #EULAR2022 @rheumnow

Difficult to treat RA? #EULAR2022 1) Active/progressive disease, unable to taper steroids, radiographic progressive, decreased QoL 2) Failure of medications (2+ b/tsDMARD after csDMARD) 3) Physician/patient perception - Fatigue: not part of definition ~5-20% pts @Rheumnow https://t.co/i5sfwoF2Gs

When will this madness stop!? TNFi to treat OA (yet again). Adalimumab for "inflammatory" knee OA. And again it doesn't work. @RheumNow #EULAR2022 OP0229 https://t.co/htwyLTYwG4

• EULAR Abstract Archive

#POS0787 #EULAR2022 More data to support the association of Anti-Ribosomal P ab with Depression + Cognitive Dysfunction using functional MRI in #lupus. To screen for neuropsychiatric in ab+ patients @RheumNow https://t.co/9JQDImrHAt

✅ #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus with SRI(4) at 32W: - DEU 3mg BID: 58.2% (p=0.0006) - DEU 6mg BID: 49.5% (p=0.021) - DEU 12mg QD: higher (but NS) vs Placebo 34.4% + secondary endpoints. https://t.co/QCWqW97tre

• Bristol Myers Squibb - Late-Breaking Data at EULAR 2022 Demonstrate Deucravaci…

#Cytokine #StormHour 🌀🌪️ #EULAR2022 #Great session by Dr.Peter Nigrovic🔥 ❓Why sJIA/AOSD often accompanied by MAS❓⚡️ #Always wondered about this!🤔 ✅Multiple mechanisms at play ✅Whats New➡️IFN gamma switch ✅mTORC1 is the NEW PIECE in the puzzle of sJIA/AOSD/MAS!🧩🧩 https://t.co/xLzCABunMb

#EULAR2022 quote of the day. I was going to go to the fatigue session @eular_org but I was too tired and burnt out! @RheumNow

Subcutaneous #methotrexate in #rheumatoidarthritis is safer and better tolerated with better continuation rates than oral #MTX #eular2022 https://t.co/cjmKntsEMe

#Lovely slide when deep into the maze of AOSD!🌎🔍❓ #EULAR2022 ⚡️Identify level of disease activity ⚡️Systemic/Articular? ⚡️Close monitoring ⚡️Identify non-responders early! ⏲️"DAVID" Project ongoing- validation of EULAR Disease Activity Score in AOSD! Exciting times ahead!🔥 https://t.co/fuPPj4lEhs

I also wonder about the significance of Ro52. Some of the commonly observed features like gastrointestinal dysmotility are not captured. https://t.co/UPljYf65vH

• Md Yuzaiful Md Yusof on Twitter: "#OP0146 #EULAR2022 Is Anti-Ro(52) ab+ on…

#EULAR2022 How to Manage (HOT): Lupus Nephritis Voclosporin is the new CNI long term reno-ischemic effects need to be looked at https://t.co/8RqayemaRu

#EULAR2022 WIN session Sarcoidosis – an update for rheumatologists Clinical Approach https://t.co/AYOEDsnDZ6

#EULAR2022 COVID orals OP0172 Swedish COVID19-Reuma registry with n=414 ARD + 61 controls RTX n=145, ABA n=21 In MVA, use of RTX, ABA were a/w lower Ab response. We've known this about RTX; growing data for ABA as well? https://t.co/Es9bA54m8E